Your browser doesn't support javascript.
loading
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.
Song, Yuqin; Sun, Mingyuan; Qi, Junyuan; Xu, Wei; Zhou, Jianfeng; Li, Dengju; Li, Jianyong; Qiu, Lugui; Du, Chenmu; Guo, Haiyi; Huang, Jane; Tang, Zhiyu; Ou, Ying; Wu, Binghao; Yu, Yiling; Zhu, Jun.
Afiliación
  • Song Y; Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Sun M; National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Qi J; National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China.
  • Li D; Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China.
  • Li J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
  • Qiu L; National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Du C; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Guo H; BeiGene USA, Inc., San Mateo, California, USA.
  • Huang J; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Tang Z; BeiGene USA, Inc., San Mateo, California, USA.
  • Ou Y; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Wu B; BeiGene USA, Inc., San Mateo, California, USA.
  • Yu Y; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Zhu J; BeiGene USA, Inc., San Mateo, California, USA.
Br J Haematol ; 198(1): 62-72, 2022 07.
Article en En | MEDLINE | ID: mdl-35383885
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies País/Región como asunto: Asia Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies País/Región como asunto: Asia Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article